Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230).

Trial Profile

Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 31 Jul 2017 to 31 Aug 2017.
    • 21 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 24 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top